Virlaza®️ is the latest development of Libi Pharm company
Virlaza® contributes to improving the symptoms associated with SARS-CoV2 (COVID-19), pneumonia, influenza, and other acute viral diseases, as follows:
reduction of the inflammation that causes a cytokine storm
body temperature regulation
relief of side effects following vaccination
relief of hypoxic state associated with coronavirus and pneumonic fever
The product may significantly alleviate the condition and reduce the symptoms associated with COVID-19, pneumonia, and influenza, shorten disease progression and prevent further complications.
Virlaza Inhibits Sars-COV-2-induced Inflammatory Response of Bronchial Epithelial Cells and Pulmonary Fibroblast
A Case Report | Virlaza™ Improves Cardiopulmonary Recovery of Post-Covid-19 Patient
Virlaza™ Improves Cardiopulmonary Recovery of Post-Covid-19 Patient: A Case Report